|
Re: RVX Announces Update Webcast and Conference Call
|
7
|
Resverlogix Corp.
|
Jan 18, 2021 07:47AM
|
|
Re: RVX AGM Q&A, post AGM-huddle, impressions
|
1
|
Resverlogix Corp.
|
Sep 19, 2018 09:01AM
|
|
Re: RVX AGM and Zenith AGM, my thoughts
|
1
|
Resverlogix Corp.
|
Sep 12, 2016 09:30PM
|
|
Re: RVX AGM 12/22/2020 - rough transcript
|
4
|
Resverlogix Corp.
|
Dec 30, 2020 07:41AM
|
|
Re: RVX 208 and the cytokine storm syndrome
|
11
|
Resverlogix Corp.
|
Apr 20, 2020 05:41AM
|
|
Re: rumours have been flying around the last ...
|
1
|
Zenith Epigenetics
|
Mar 01, 2021 06:40AM
|
|
Re: Rules of thumb and broken thumbs...
|
3
|
Resverlogix Corp.
|
Sep 30, 2020 11:52AM
|
|
Re: RRSP to TFSA
|
|
Zenith Epigenetics
|
Mar 06, 2019 02:20PM
|
|
Re: Rothschild Engagement – What’s the Strategy?
|
2
|
Resverlogix Corp.
|
Jan 20, 2019 12:47PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
9
|
Resverlogix Corp.
|
Jun 14, 2020 08:32AM
|
|
Re: Reverse Split, the good, bad and in between....
|
3
|
Resverlogix Corp.
|
Aug 15, 2018 06:26AM
|
|
Re: Reverse Split, the good, bad and in between....
|
3
|
Resverlogix Corp.
|
Aug 15, 2018 10:46AM
|
|
Re: Reverse Split, the good, bad and in between....
|
6
|
Resverlogix Corp.
|
Aug 14, 2018 11:37AM
|
|
Re: Reverse Split, the good, bad and in between....
|
6
|
Resverlogix Corp.
|
Aug 14, 2018 05:59PM
|
|
Re: Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
|
2
|
Resverlogix Corp.
|
Apr 18, 2019 03:57PM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
12
|
Resverlogix Corp.
|
Aug 22, 2022 09:48AM
|
|
Re: Resverlogix poster from ASN 2016
|
|
Resverlogix Corp.
|
Nov 21, 2016 04:28PM
|
|
Re: Resverlogix H2 2018 events
|
1
|
Resverlogix Corp.
|
Aug 29, 2018 09:14AM
|
|
Re: Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
|
5
|
Resverlogix Corp.
|
Jul 26, 2017 04:03PM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
4
|
Resverlogix Corp.
|
Mar 19, 2018 08:23AM
|
